Hawaii Pacific Neuroscience LLC

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease2 trials
• Multiple sclerosis2 trials
• Parkinson disease2 trials
• Epilepsy1 trial

Phase

• Phase 33 trials
• Phase 22 trials
• Phase 2/32 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals3 trials
• Annovis Bio Inc.2 trials
• Biogen1 trial
• Jazz Pharmaceuticals1 trial

Running trials

• Recruiting

  A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

  NCT07723963· Phase 2/3· Jazz Pharmaceuticals· Source

  Contact: Clinical Trial Disclosure & Transparency

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Gina McNarney

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

  NCT07094516· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy1 recruiting
• Multiple sclerosis1 recruiting

Closed trials

• Completed

  A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

  NCT05686044· Phase 2/3· Annovis Bio Inc.· Source

• Completed

  A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

  NCT05357989· Phase 3· Annovis Bio Inc.· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source